Valuation: Fulgent Genetics, Inc.

Market Cap 586M 507M 480M 434M 815M 56.17B 821M 5.72B 2.2B 28.48B 2.2B 2.15B 90.83B P/E 2026 *
-
P/E 2027 * -
Enterprise Value 586M 507M 480M 434M 815M 56.17B 821M 5.72B 2.2B 28.48B 2.2B 2.15B 90.83B EV / Sales 2026 *
1.77x
EV / Sales 2027 * 1.53x
Free-Float
48.86%
Yield 2026 *
-
Yield 2027 * -
1 day+3.05%
1 week+5.35%
Current month+9.86%
1 month+14.66%
3 months+15.97%
6 months+44.08%
Current year-19.00%
1 week 19.46
Extreme 19.46
21.31
1 month 18.28
Extreme 18.28
21.31
Current year 13.46
Extreme 13.46
28.95
1 year 13.46
Extreme 13.46
31.04
3 years 13.46
Extreme 13.46
31.04
5 years 13.46
Extreme 13.46
109.55
10 years 2.72
Extreme 2.725
189.89
Manager TitleAgeSince
President 59 03/05/2022
Chief Executive Officer 70 13/05/2016
Director of Finance/CFO 58 01/01/2016
Director TitleAgeSince
Chairman 70 01/09/2016
Director/Board Member 76 01/08/2019
Director/Board Member 57 01/08/2022
Date Insider Type Main position Quantity % Market Cap. Importance
9/2/26 A Sell

Founder

-2,127 0.0069%
9/2/26 A Sell

Chief Technology Officer

-1,673 0.0055%
9/1/26 A Tax

Chief Financial Officer

-2,087 0.0068%
Change 5-day change 1-year change 3-year change Capi.($)
+3.05%+5.35%-3.18%-28.28% 586M
+2.63%+8.22%+103.75%+581.13% 50.56B
+2.75%-0.27%+17.64%+60.66% 26.27B
+0.98%+0.21%-13.04%-36.97% 6.82B
+2.16%+7.16%+2.84%+170.50% 6.07B
-0.56%-1.25%+15.93%+60.54% 3.32B
+5.46%+10.21%-22.45%+2,060.73% 2.82B
+2.61%+7.57%+133.79%+40.34% 2.43B
-0.56%+2.41%+36.67%+45.45% 2.25B
-2.11%+1.47%-16.12%-55.03% 1.83B
Average +1.64%+3.20%+25.58%+289.91% 10.3B
Weighted average by Cap. +2.35%+2.73%+58.31%+367.73%

Financials

2026 *2027 *
Net sales 332M 287M 272M 246M 462M 31.82B 465M 3.24B 1.25B 16.13B 1.25B 1.22B 51.45B 383M 331M 313M 284M 533M 36.71B 537M 3.74B 1.44B 18.61B 1.44B 1.41B 59.36B
Net income -112M -97.01M -91.74M -83.05M -156M -10.74B -157M -1.09B -421M -5.45B -421M -411M -17.37B -79M -68.43M -64.71M -58.58M -110M -7.58B -111M -772M -297M -3.84B -297M -290M -12.25B
Net Debt - -
Logo Fulgent Genetics, Inc.
Fulgent Genetics, Inc. is a technology-based company with a laboratory services business and a therapeutic development business. Its laboratory services business includes technical laboratory and testing services and professional interpretation of laboratory results by licensed physicians. Its therapeutic development business is focused on developing drug candidates for treating a range of cancers using a novel nanoencapsulation and targeted therapy platform designed to improve the therapeutic window and pharmacokinetic profile of new and existing cancer drugs. Its testing services include comprehensive anatomic pathology testing services, including gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology, and precision diagnostics testing services, including next-generation sequencing (NGS), tests for biopharma research and clinical tests for rare disease, hereditary cancer, reproductive health, and many other diseases.
Employees
1,315
Date Price Change Volume
15/09/26 $21.28 +3.05% 479,940
14/09/26 $20.65 +0.98% 336,331
11/09/26 $20.45 +1.64% 380,509
10/09/26 $20.12 +1.36% 337,288
09/09/26 $19.85 -1.73% 369,944
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
1
Last Close Price
21.28USD
Average target price
19.00USD
Spread / Average Target
-10.71%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. FLGT Stock
LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!